EDGE
Get a demo
Log In
All Updates

All Updates

icon
Filter
M&A
MilliporeSigma acquires Mirus Bio for USD 600 million to enhance viral vector manufacturing capabilities
Cell & Gene Therapy
May 23, 2024
This week:
Product updates
Stability AI launches Stable Diffusion 3 Medium, a text-to-image model
Foundation Models
Yesterday
Product updates
Microsoft discontinues GPT Builder in Copilot
Generative AI Applications
Yesterday
Funding
BlinqIO raises USD 5 million in funding to expand operations
Generative AI Applications
Yesterday
Product updates
Databricks launches innovations to Mosaic AI for production-quality applications
Generative AI Infrastructure
Yesterday
M&A
Rebellions and Sapeon Korea merge to challenge global AI chip leader
Generative AI Infrastructure
Yesterday
M&A
Pluxee to acquire Cobee; expands employee benefits offering
Remote Work Infrastructure
Yesterday
Product updates
Space and Time launches 'Proof of SQL' solution on GitHub
Enterprise Blockchain Solutions
Yesterday
Partnerships
Lido partners with Mellow Finance to launch liquid restaking vaults
Decentralized Finance (DeFi)
Yesterday
Funding
Rivia raises EUR 3 million in seed funding
Clinical Trial Technology
Yesterday
Partnerships
Product updates
Databricks and Shutterstock collaborate to launch enterprise-optimized ImageAI model
Generative AI Infrastructure
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

May 23, 2024

MilliporeSigma acquires Mirus Bio for USD 600 million to enhance viral vector manufacturing capabilities

M&A

  • MilliporeSigma, the Life Science business branch of Merck KGaA (based in the US and Canada), has finalized a deal to buy Mirus Bio for USD 600 million.

  • Mirus Bio is known for its expertise in the development and commercialization of transfection re-agents, under the name TransIT-VirusGEN, which are instrumental in transferring genetic material into cells. This makes them essential in the creation of viral vectors, a crucial element in the design of cell and gene therapies.

  • This acquisition is intended to bolster Merck's capabilities in viral vector manufacturing for gene and cell therapies. With the added competency of Mirus Bio, Merck aims to provide comprehensive solutions for all phases of viral vector manufacturing, thereby supporting the progression of cell and gene therapies from preliminary stages to final commercial production.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.